229 related articles for article (PubMed ID: 28811376)
1. In vivo loss-of-function screens identify KPNB1 as a new druggable oncogene in epithelial ovarian cancer.
Kodama M; Kodama T; Newberg JY; Katayama H; Kobayashi M; Hanash SM; Yoshihara K; Wei Z; Tien JC; Rangel R; Hashimoto K; Mabuchi S; Sawada K; Kimura T; Copeland NG; Jenkins NA
Proc Natl Acad Sci U S A; 2017 Aug; 114(35):E7301-E7310. PubMed ID: 28811376
[TBL] [Abstract][Full Text] [Related]
2. Network analysis identifies an HSP90-central hub susceptible in ovarian cancer.
Liu H; Xiao F; Serebriiskii IG; O'Brien SW; Maglaty MA; Astsaturov I; Litwin S; Martin LP; Proia DA; Golemis EA; Connolly DC
Clin Cancer Res; 2013 Sep; 19(18):5053-67. PubMed ID: 23900136
[TBL] [Abstract][Full Text] [Related]
3. KPNB1 inhibition disrupts proteostasis and triggers unfolded protein response-mediated apoptosis in glioblastoma cells.
Zhu ZC; Liu JW; Li K; Zheng J; Xiong ZQ
Oncogene; 2018 May; 37(22):2936-2952. PubMed ID: 29520102
[TBL] [Abstract][Full Text] [Related]
4. Targeting KPNB1 with Genkwadaphnin suppresses gastric cancer progression through the Nur77-mediated signaling pathway.
Zhang C; Wang X; Cai G; Wang H; Liu Q; Ma S; Sun H; An Y; Miao M; Yin S; Liu P; Wang X; Wang J
Eur J Pharmacol; 2024 May; ():176697. PubMed ID: 38823760
[TBL] [Abstract][Full Text] [Related]
5. Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactions.
Lord CJ; Quinn N; Ryan CJ
Elife; 2020 May; 9():. PubMed ID: 32463358
[TBL] [Abstract][Full Text] [Related]
6. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.
Burr ML; Sparbier CE; Chan YC; Williamson JC; Woods K; Beavis PA; Lam EYN; Henderson MA; Bell CC; Stolzenburg S; Gilan O; Bloor S; Noori T; Morgens DW; Bassik MC; Neeson PJ; Behren A; Darcy PK; Dawson SJ; Voskoboinik I; Trapani JA; Cebon J; Lehner PJ; Dawson MA
Nature; 2017 Sep; 549(7670):101-105. PubMed ID: 28813417
[TBL] [Abstract][Full Text] [Related]
7. Genome-Wide CRISPR Screen for Essential Cell Growth Mediators in Mutant KRAS Colorectal Cancers.
Yau EH; Kummetha IR; Lichinchi G; Tang R; Zhang Y; Rana TM
Cancer Res; 2017 Nov; 77(22):6330-6339. PubMed ID: 28954733
[TBL] [Abstract][Full Text] [Related]
8. A CRISPR Activation Screen Identifies a Pan-avian Influenza Virus Inhibitory Host Factor.
Heaton BE; Kennedy EM; Dumm RE; Harding AT; Sacco MT; Sachs D; Heaton NS
Cell Rep; 2017 Aug; 20(7):1503-1512. PubMed ID: 28813663
[TBL] [Abstract][Full Text] [Related]
9. A Broad-Spectrum Inhibitor of CRISPR-Cas9.
Harrington LB; Doxzen KW; Ma E; Liu JJ; Knott GJ; Edraki A; Garcia B; Amrani N; Chen JS; Cofsky JC; Kranzusch PJ; Sontheimer EJ; Davidson AR; Maxwell KL; Doudna JA
Cell; 2017 Sep; 170(6):1224-1233.e15. PubMed ID: 28844692
[TBL] [Abstract][Full Text] [Related]
10. Polylox barcoding reveals haematopoietic stem cell fates realized in vivo.
Pei W; Feyerabend TB; Rössler J; Wang X; Postrach D; Busch K; Rode I; Klapproth K; Dietlein N; Quedenau C; Chen W; Sauer S; Wolf S; Höfer T; Rodewald HR
Nature; 2017 Aug; 548(7668):456-460. PubMed ID: 28813413
[TBL] [Abstract][Full Text] [Related]
11. CRISPR-FOCUS: A web server for designing focused CRISPR screening experiments.
Cao Q; Ma J; Chen CH; Xu H; Chen Z; Li W; Liu XS
PLoS One; 2017; 12(9):e0184281. PubMed ID: 28873439
[TBL] [Abstract][Full Text] [Related]
12. Discovery of stimulation-responsive immune enhancers with CRISPR activation.
Simeonov DR; Gowen BG; Boontanrart M; Roth TL; Gagnon JD; Mumbach MR; Satpathy AT; Lee Y; Bray NL; Chan AY; Lituiev DS; Nguyen ML; Gate RE; Subramaniam M; Li Z; Woo JM; Mitros T; Ray GJ; Curie GL; Naddaf N; Chu JS; Ma H; Boyer E; Van Gool F; Huang H; Liu R; Tobin VR; Schumann K; Daly MJ; Farh KK; Ansel KM; Ye CJ; Greenleaf WJ; Anderson MS; Bluestone JA; Chang HY; Corn JE; Marson A
Nature; 2017 Sep; 549(7670):111-115. PubMed ID: 28854172
[TBL] [Abstract][Full Text] [Related]
13. In Situ Capture of Chromatin Interactions by Biotinylated dCas9.
Liu X; Zhang Y; Chen Y; Li M; Zhou F; Li K; Cao H; Ni M; Liu Y; Gu Z; Dickerson KE; Xie S; Hon GC; Xuan Z; Zhang MQ; Shao Z; Xu J
Cell; 2017 Aug; 170(5):1028-1043.e19. PubMed ID: 28841410
[TBL] [Abstract][Full Text] [Related]
14. Small molecules enhance CRISPR/Cas9-mediated homology-directed genome editing in primary cells.
Li G; Zhang X; Zhong C; Mo J; Quan R; Yang J; Liu D; Li Z; Yang H; Wu Z
Sci Rep; 2017 Aug; 7(1):8943. PubMed ID: 28827551
[TBL] [Abstract][Full Text] [Related]
15. Use of CRISPR-modified human stem cell organoids to study the origin of mutational signatures in cancer.
Drost J; van Boxtel R; Blokzijl F; Mizutani T; Sasaki N; Sasselli V; de Ligt J; Behjati S; Grolleman JE; van Wezel T; Nik-Zainal S; Kuiper RP; Cuppen E; Clevers H
Science; 2017 Oct; 358(6360):234-238. PubMed ID: 28912133
[TBL] [Abstract][Full Text] [Related]
16. Engineering CRISPR-Cpf1 crRNAs and mRNAs to maximize genome editing efficiency.
Li B; Zhao W; Luo X; Zhang X; Li C; Zeng C; Dong Y
Nat Biomed Eng; 2017 May; 1(5):. PubMed ID: 28840077
[TBL] [Abstract][Full Text] [Related]
17. Enhanced proofreading governs CRISPR-Cas9 targeting accuracy.
Chen JS; Dagdas YS; Kleinstiver BP; Welch MM; Sousa AA; Harrington LB; Sternberg SH; Joung JK; Yildiz A; Doudna JA
Nature; 2017 Oct; 550(7676):407-410. PubMed ID: 28931002
[TBL] [Abstract][Full Text] [Related]
18. A genome-wide comprehensive analysis of alterations in driver genes in non-small-cell lung cancer.
Yi J; Wei X; Li X; Wan L; Dong J; Wang R
Anticancer Drugs; 2018 Jan; 29(1):10-18. PubMed ID: 29084003
[TBL] [Abstract][Full Text] [Related]
19. Dense sgRNA Library Construction Using a Molecular Chipper Approach.
Cheng J; Pan W; Lu J
Bio Protoc; 2017 Jun; 7(12):. PubMed ID: 28835906
[TBL] [Abstract][Full Text] [Related]
20. Genome editing: CRISPR-Cas becoming more human.
Baumann K
Nat Rev Mol Cell Biol; 2017 Oct; 18(10):591. PubMed ID: 28811667
[No Abstract] [Full Text] [Related]
[Next] [New Search]
